BFM
SRPT icon

Boston Financial Management’s Sarepta Therapeutics SRPT Stock Holding History

Boston Financial Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,468
Closed -$242K – 206
2014
Q3 		$242K Sell
11,468
-895
-7% -$20.2K 0.03% 188
2014
Q2 		$368K Sell
12,363
-900
-7% -$28.4K 0.05% 176
2014
Q1 		$319K Sell
13,263
-55
-0.4% -$1.4K 0.04% 176
2013
Q4 		$271K Sell
13,318
-7,422
-36% -$221K 0.04% 187
2013
Q3 		$980K Buy
20,740
+12,662
+157% +$488K 0.15% 135
2013
Q2 		$307K Buy
+8,078
New +$289K 0.05% 179

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Boston Financial Management's SRPT Position: Q4 2014 in Review

Boston Financial Management sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 11,468 shares — an estimated $242K sold.

Boston Financial Management first reported a position in SRPT in Q2 2013 and held it in 6 quarters. The position peaked at $980K in Q3 2013. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Boston Financial Management reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Boston Financial Management sold 11,468 Sarepta Therapeutics shares in Q4 2014, an estimated $242K.
  • Boston Financial Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 6 quarters.
  • Boston Financial Management's Sarepta Therapeutics position peaked at $980K in Q3 2013.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Boston Financial Management's 13F filing for Q4 2014, filed 18 Feb 2015.